diclofenamide Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Diclorphenamide, a carbonic anhydrase inhibitor, was initially developed for the treatment of glaucome, however, now it is used for patients suffering from primary hypokalemic and hyperkalemic periodic paralysis. The exact mechanism of diclorphenamide in periodic paralysis is unknown.   NCATS

Chemistry

  • SMILES: NS(=O)(=O)C1=CC(Cl)=C(Cl)C(=C1)S(N)(=O)=O
  • InChIKey: GJQPMPFPNINLKP-UHFFFAOYSA-N
  • Mol. Mass: 305.159
  • ALogP: 0.6
  • ChEMBL Molecules:
    bromisovalum  
    dichlorphenamide  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$100.1880
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

1,3-disulfamoyl-4,5-dichlorobenzene | 1,3-disulfamyl-4,5-dichlorobenzene | 3,4-dichloro-5-sulfamylbenzenesulfonamide | 4,5-dichloro-1,3-benzenedisulfonamide | 4,5-dichloro-1,3-disulfamoylbenzene | 4,5-dichlorobenzene-1,3-disulfonamide | 4,5-dichloro-benzene-1,3-disulfonic acid diamide | 4,5-dichloro-m-benzenedisulfonamide | daranide | dichlofenamide | dichlorophenamide | dichlorphenamide | diclofenamid | diclofenamida | diclofenamide | diclofenamidum | glaucol | oratrol

Organizations (8)

Research & Development (4)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (4)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (3)

Approved Indications (2)


 

Hypokalemic Periodic Paralysis (approved 1958)

Paralysis, Hyperkalemic Periodic (approved 1958)

Experimental Indications - Clinical Trial Phases 1-4 (3)


 

Hypokalemic Periodic Paralysis (Phase 3)

Myotonic Disorders (Phase 3)

Paralysis, Hyperkalemic Periodic (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial Organizations: 4

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue